Form 4: Director Paul Bisaro Increases Stake in Myriad Genetics

Director Paul Bisaro purchased 7,500 shares of Myriad Genetics common stock at an average price of $3.685 per share.

Summary

• Director Paul Bisaro acquired 7,500 shares of Myriad Genetics (MYGN) common stock.
• The transaction occurred on May 14, 2026.
• The purchase price was $3.685 per share.
• Following this transaction, the director's total beneficial ownership increased to 97,441 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mildly positive signal, as director-level insider buying typically reflects confidence in the company's underlying value.

Positives

• Insider buying often signals management confidence in the company's future prospects and valuation.
• The director increased their direct equity stake in the company.

Negatives

• None identified in this filing.

Risks

• Market volatility affecting the value of equity holdings.
• General risks associated with the biotechnology and genetic testing industry.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that insider purchases by board members are generally viewed as a positive indicator of internal sentiment regarding the company's long-term strategic direction and current market valuation.

Comparison to Industry Standards

• Insider buying is a standard practice among corporate directors to align interests with shareholders.
• The volume of shares purchased is relatively small compared to total outstanding shares, which is typical for individual director transactions.

Stakeholder Impact

• Shareholders may view the director's investment as a vote of confidence in the company's current trajectory.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Myriad Genetics, MYGN, Insider Trading, Form 4, Director Purchase, Equity Ownership